Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

Dr. Rekha Kumar, endocrinologist and obesity medicine expert at Weill Cornell Medicine, joined ABC News Live to discuss the ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

Injectable drugs require refrigeration when they are stored or transported, and the pill potentially opens up the market ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

A new clinical trial is showing promising results for a new pill to help treat diabetes and support weight loss. CBS News ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...